MDS 2021 | Clinical targets for successful iron chelation therapy
Heather Leitch, MD, PhD, FRCPC, St. Paul’s Hospital, Vancouver, Canada, provides an overview of her talk on the clinical targets for iron chelation therapy, a method to treat iron overload by promoting increased excretion. The current clinical targets include serum ferritin levels, a very widely used convenient measure in clinical practice, as well as measures of oxidative stress such as plasma-labeled iron. Dr Leitch explains that she will also be sharing new data at the 16th International Congress on Myelodysplastic Syndromes from the Canadian registry on transference saturation and its relation to clinical outcomes. Dr Leitch will also propose new criteria for iron overload severity and for reporting iron chelation therapy status by region.
Disclosures
Heather Leitch, MD, PhD, FRCPC, has received honoraria, participated in advisory boards with, or received research funding from AbbVie, Alexion, Astra Zeneca, BMS, Celgene, Janssen, Novartis and Taiho.
